Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;26(5):1197-216.
doi: 10.1007/s11095-008-9694-0. Epub 2008 Aug 29.

Recent perspectives in ocular drug delivery

Affiliations
Review

Recent perspectives in ocular drug delivery

Ripal Gaudana et al. Pharm Res. 2009 May.

Abstract

Anatomy and physiology of the eye makes it a highly protected organ. Designing an effective therapy for ocular diseases, especially for the posterior segment, has been considered as a formidable task. Limitations of topical and intravitreal route of administration have challenged scientists to find alternative mode of administration like periocular routes. Transporter targeted drug delivery has generated a great deal of interest in the field because of its potential to overcome many barriers associated with current therapy. Application of nanotechnology has been very promising in the treatment of a gamut of diseases. In this review, we have briefly discussed several ocular drug delivery systems such as microemulsions, nanosuspensions, nanoparticles, liposomes, niosomes, dendrimers, implants, and hydrogels. Potential for ocular gene therapy has also been described in this article. In near future, a great deal of attention will be paid to develop non-invasive sustained drug release for both anterior and posterior segment eye disorders. A better understanding of nature of ocular diseases, barriers and factors affecting in vivo performance, would greatly drive the development of new delivery systems. Current momentum in the invention of new drug delivery systems hold a promise towards much improved therapies for the treatment of vision threatening disorders.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structure of eye.
Fig. 2
Fig. 2
Routes of ocular drug delivery.

Similar articles

Cited by

References

    1. Hughes PM, Mitra AK. Overview of ocular drug delivery and iatrogenic ocular cytopathologies. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. 2nd. New York: M Dekker, Inc; 1993. pp. 1–27.
    1. Lang JC. Ocular drug delivery: conventional ocular formulations. Adv Drug Delivery Rev. 1995;16:39–43.
    1. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems—recent advances. Prog Retin Eye Res. 1998;17:33–58. doi: 10.1016/S1350-9462(97)00002-5. - DOI - PubMed
    1. Jain R, Majumdar S, Nashed Y, Pal D, Mitra AK. Circumventing Pglycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol Pharm. 2004;1:290–299. - PubMed
    1. Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4:371–388. - PubMed

Publication types